RxDoctor Payments Data

Thushara Paul, MD

Hematology & Oncology · Columbus, OHNPI 1518370709

Payments from drug & device makers

$791in general payments, 2019–2025

Across 34 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$159
  • Eisai Inc.$127
  • Amgen$112
  • AstraZeneca$102
  • Astellas Pharma US Inc$57
  • Gilead$43
  • plus $191 from 8 others

What the payments were for

  • Food & beverage$68687%
  • Education$10613%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$791 in reported general payments places this provider in the 25th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$63,105
Medicare patients
248
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide35$648,822
ErleadaApalutamide29$450,024
TagrissoOsimertinib Mesylate22$381,056
NubeqaDarolutamide20$277,482
IbrancePalbociclib15$235,188
ImbruvicaIbrutinib11$180,721
CalquenceAcalabrutinib Maleate13$162,506
VenclextaVenetoclax11$160,883
Lenalidomide12$141,608
JakafiRuxolitinib Phosphate16$108,275
EliquisApixaban22$16,400
Dexamethasone97$1,594
Prochlorperazine Maleate99$1,024
Hydroxyurea48$1,021
Ondansetron Hcl21$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$102$543,56235 claims
Johnson & JohnsonErleada$21$450,02429 claims
BayerNubeqa$21$277,48220 claims
PfizerIbrance, Eliquis$25$251,58837 claims
Incyte CorporationJakafi$21$108,27516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →